4//SEC Filing
O'Keeffe Charles B 4
Accession 0001161697-23-000133
CIK 0001369568other
Filed
Feb 16, 7:00 PM ET
Accepted
Feb 17, 5:01 PM ET
Size
7.4 KB
Accession
0001161697-23-000133
Insider Transaction Report
Form 4
O'Keeffe Charles B
Director
Transactions
- Exercise/Conversion
Common Stock, par value $0.001 per share
2023-02-15+4,000→ 620,391 total - Exercise/Conversion
Restricted Stock Units
2023-02-15−4,000→ 260,500 total→ Common Stock (4,000 underlying)
Footnotes (3)
- [F1]Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
- [F2]Derivative securities vest in equal tranches, 1/3rd on February 14, 2023, 1/3rd on February 14, 2024 and 1/3rd on February 14, 2025.
- [F3]Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on February 15, 2023.
Documents
Issuer
CATALYST PHARMACEUTICALS, INC.
CIK 0001369568
Entity typeother
Related Parties
1- filerCIK 0001378656
Filing Metadata
- Form type
- 4
- Filed
- Feb 16, 7:00 PM ET
- Accepted
- Feb 17, 5:01 PM ET
- Size
- 7.4 KB